The funding Solar Foods received was not a surprise to us, given the progress of Solein's commercialization.

The change of CEO seems to be a logical decision as Solar Foods moves from the product development phase to the commercialization phase, which requires a different set of skills from the CEO.

The Solar Foods Capital Markets Day provided a concrete insight into Solein's commercialization process, the upcoming 02 factory investment and the company's financial targets. The content of the Capital Markets Day focused on Solar Foods' role as a manufacturer of Solein, which is a capital-intensive route to scaling the business.

In its CMD, Solar Foods presented its strategic priorities, Solein’s commercialization process, technology projects and its financial targets for 2027-2030 and 2031-2035.

In its 2025-2030 strategy period, Solar Foods will focus in particular on the Health & Performance Nutrition segment in the US, where its spearhead product, Solein, was approved during the fall.